Aymen I Idris

List of Publications by Year
in descending order

62	2,068	304743	233421
papers	citations	22 h-index	45 g-index

66	66	66	2443
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nature Medicine, 2005, 11, 774-779.	30.7	330
2	Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro. Calcified Tissue International, 2008, 82, 191-201.	3.1	187
3	Cannabinoid Receptor Type 1 Protects against Age- Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells. Cell Metabolism, 2009, 10, 139-147.	16.2	151
4	Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor. Endocrinology, 2008, 149, 5619-5626.	2.8	134
5	The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone, 2010, 46, 1089-1099.	2.9	103
6	Pharmacologic inhibitors of IÎºB kinase suppress growth and migration of mammary carcinosarcoma cellsin vitroand prevent osteolytic bone metastasisin vivo. Molecular Cancer Therapeutics, 2009, 8, 2339-2347.	4.1	94
7	The Type 2 Cannabinoid Receptor Regulates Bone Mass and Ovariectomy-Induced Bone Loss by Affecting Osteoblast Differentiation and Bone Formation. Endocrinology, 2011, 152, 2141-2149.	2.8	92
8	Î²2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Archives of Biochemistry and Biophysics, 2009, 482, 96-103.	3.0	72
9	Role of cannabinoids in the regulation of bone remodeling. Frontiers in Endocrinology, 2012, 3, 136.	3.5	70
10	Rodent models of osteoporosis. BoneKEy Reports, 2014, 3, 614.	2.7	65
11	Cannabinoids and Bone: Friend or Foe?. Calcified Tissue International, 2010, 87, 285-297.	3.1	61
12	Ovariectomy/Orchidectomy in Rodents. Methods in Molecular Biology, 2012, 816, 545-551.	0.9	60
13	A Comparison between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function In Vitro and Ovariectomy-Induced Bone Loss In Vivo. Calcified Tissue International, 2007, 81, 403-413.	3.1	55
14	Small molecule inhibitors of IÎºB kinase signaling inhibit osteoclast formationin vitroand prevent ovariectomyâ€induced bone lossin vivo. FASEB Journal, 2010, 24, 4545-4555.	0.5	51
15	Combined deficiency of the Cnr1 and Cnr2 receptors protects against ageâ€related bone loss by osteoclast inhibition. Aging Cell, 2017, 16, 1051-1061.	6.7	39
16	Hydrogen sulphideâ€releasing diclofenac derivatives inhibit breast cancerâ€induced osteoclastogenesis in vitro and prevent osteolysis ex vivo. British Journal of Pharmacology, 2012, 165, 1914-1925.	5.4	34
17	Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. Journal of Biological Chemistry, 2015, 290, 22049-22060.	3.4	33
18	Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. Pharmacological Research, 2017, 119, 391-403.	7.1	31

#	Article	IF	Citations
19	TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis. Scientific Reports, 2018, 8, 39.	3.3	30
20	Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine, 2019, 44, 452-466.	6.1	30
21	Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Current Neuropharmacology, 2010, 8, 243-253.	2.9	26
22	Raman spectroscopy predicts the link between claw keratin and bone collagen structure in a rodent model of oestrogen deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 398-406.	3.8	26
23	Genetic Background Modifies the Effects of Type 2 Cannabinoid Receptor Deficiency on Bone Mass and Bone Turnover. Calcified Tissue International, 2014, 94, 259-268.	3.1	21
24	Pharmacological inhibition of the IKKÎµ/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 2019, 450, 76-87.	7.2	20
25	Ovariectomy/Orchiectomy in Rodents. Methods in Molecular Biology, 2019, 1914, 261-267.	0.9	19
26	Identification of Biphenylcarboxylic Acid Derivatives as a Novel Class of Bone Resorption Inhibitors. Journal of Bone and Mineral Research, 2004, 19, 1651-1660.	2.8	17
27	Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption. Journal of Medicinal Chemistry, 2006, 49, 7487-7492.	6.4	17
28	ABD56 causes osteoclast apoptosis by inhibiting the NFÎºB and ERK pathways. Biochemical and Biophysical Research Communications, 2008, 371, 94-98.	2.1	17
29	Pharmacological Inhibition of NFÎºB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo. Calcified Tissue International, 2019, 105, 193-204.	3.1	17
30	Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancerâ€“induced bone cell activity, bone remodeling, and osteolysis. Journal of Bone and Mineral Research, 2013, 28, 1229-1242.	2.8	15
31	Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 2020, 488, 27-39.	7.2	15
32	Identification of Novel Biphenyl Carboxylic Acid Derivatives as Novel Antiresorptive Agents that Do Not Impair Parathyroid Hormone-Induced Bone Formation. Endocrinology, 2009, 150, 5-13.	2.8	14
33	The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. European Journal of Pharmacology, 2009, 602, 215-222.	3.5	13
34	Modulation of Strain-Specific Differences in Gene Expression by Cannabinoid Type 2 Receptor Deficiency. Calcified Tissue International, 2014, 94, 423-432.	3.1	13
35	The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production. Bone, 2004, 35, 636-643.	2.9	11
36	Pharmacological evidence for the bone-autonomous contribution of the NFÎºB/Î²-catenin axis to breast cancer related osteolysis. Cancer Letters, 2017, 410, 180-190.	7.2	10

#	Article	IF	Citations
37	JZL184, A Monoacylglycerol Lipase Inhibitor, Induces Bone Loss in a Multiple Myeloma Model of Immunocompetent Mice. Calcified Tissue International, 2020, 107, 72-85.	3.1	9
38	Role of Cannabinoid Receptors in Bone Disorders: Alternatives for Treatment. , 2008, 21, 533.		9
39	The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. BoneKEy Reports, 2012, 1, 224.	2.7	8
40	Pharmacological Inhibition of the Skeletal IKKÎ² Reduces Breast Cancer-Induced Osteolysis. Calcified Tissue International, 2018, 103, 206-216.	3.1	8
41	Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A. Scientific Reports, 2018, 8, 6877.	3.3	8
42	The Biphenyl-Carboxylate Derivative ABD328 is a Novel Orally Active Antiresorptive Agent. Calcified Tissue International, 2010, 87, 525-532.	3.1	7
43	Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis. Journal of Materials Science: Materials in Medicine, 2019, 30, 25.	3.6	6
44	Regulation of breast cancer induced bone disease by cancer-specific IKKÎ². Oncotarget, 2018, 9, 16134-16148.	1.8	6
45	Association of cannabinoid receptor modulation with normal and abnormal skeletal remodelling: A systematic review and meta-analysis of in vitro, in vivo and human studies. Pharmacological Research, 2022, 175, 105928.	7.1	5
46	P52. The IKK inhibitors celastrol and parthenolide inhibit breast cancer cell proliferation and migration in vitro and osteolytic bone metastasis in vivo. Cancer Treatment Reviews, 2008, 34, 75.	7.7	2
47	Analysis of Signalling Pathways by Western Blotting and Immunoprecipitation. Methods in Molecular Biology, 2012, 816, 223-232.	0.9	2
48	Analysis of Signaling Pathways by Western Blotting and Immunoprecipitation. Methods in Molecular Biology, 2019, 1914, 131-143.	0.9	2
49	Anti-inflammatory, but not osteoprotective, effect of the TRAF6/CD40 inhibitor 6877002 in rodent models of local and systemic osteolysis. Biochemical Pharmacology, 2022, 195, 114869.	4.4	2
50	A novel profile analysis of metaphyseal trabecular bone reveals a biphasic dose-dependent response to administered bone active agents. Bone, 2008, 43, S19.	2.9	0
51	The promise and dilemma of cannabinoid therapy: Lessons from animal studies of bone disease. IBMS BoneKEy, 2011, 8, 84-95.	0.0	0
52	Genetic inactivation and pharmacological inhibition of IKKÎ² activity in cancer cells inhibit breast cancer-induced osteoclastogenesis, promotes osteoblast differentiation and prevents osteolysis. Bone, 2012, 50, S51.	2.9	0
53	Recent Trends and Advances in Cancer-Induced Bone Disease. Calcified Tissue International, 2018, 102, 129-130.	3.1	0
54	Effects of NF-Î²B manipulation on cancer-associated bone disease. , 2022, , 241-251.		0

#	Article	IF	Citations
55	Role of classical cannabinoid receptors in cancer-associated bone disease. , 2022, , 295-303.		0
56	Nail Testing Detects Bone Loss In Mice: Implications For Osteoporosis And Beyond. , 2017, , .		0
57	Therapeutic Targeting Of Marijuana Receptors: Type 1, 2 Or Both - That Is The Question. , 2017, , .		0
58	The Dilemma Of Targeting NFÎºB For The Treatment Of Secondary Cancer In Bone. , 2017, , .		0
59	TRAFficking Of Breast Cancer Cells To Bone. , 2018, , .		0
60	The Ebb And Flow Of Therapeutic Targeting Of NFÎºB In Cancer. , 2018, , .		0
61	A Cautionary Tale About Therapeutic Manipulation Of Bone Formation. , 2018, , .		0
62	Role of NFÎºB in Bone Remodeling in Health and Cancer. , 2020, , 294-304.		0